Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$884.74 USD

884.74
1,163,785

-6.33 (-0.71%)

Updated Oct 3, 2024 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2

by Zacks Equity Research

Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the second quarter of 2019.

Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Nektar's (NKTR) reports narrower-than expected loss in the second quarter but stock declines.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients

by Kinjel Shah

Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.

Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2019.

Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss

by Zacks Equity Research

Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.

Radius (RDUS) Q2 Earnings Beat Estimates, Tymlos Sales Solid

by Zacks Equity Research

Radius (RDUS) reports a narrower-then-expected loss and beats sales estimates in the second quarter of 2019.

Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down

by Zacks Equity Research

Teva Pharmaceutical (TEVA) posts better-than-expected results. However, earnings and sales decline year over year.

Kalyan Nandy headshot

Top Stock Reports: Disney, Eli Lilly, ADP & More

by Kalyan Nandy

Today's Research Daily features updated research reports on 16 major stocks, including Disney (DIS), Eli Lilly (LLY) and ADP (ADP).

Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up

by Zacks Equity Research

Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.

Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates

by Zacks Equity Research

Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.

Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2

by Zacks Equity Research

Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.

Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger

by Kinjel Shah

AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.

United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y

by Zacks Equity Research

United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.

Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine

by Zacks Equity Research

Amgen (AMGN) beats estimates for earnings and sales in the second quarter. Higher demand for new growth drivers was offset by the erosion of mature brands from brand/biosimilar competition.

Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.

Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up

by Zacks Equity Research

Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.

Economic and Earnings Date Deluge

by Zacks Equity Research

Economic and Earnings Date Deluge

Mark Vickery headshot

Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More

by Mark Vickery

Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.

Eli Lilly (LLY) Tops Q2 Earnings Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of 2.74% and -0.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Sanofi (SNY) Q2 Earnings Top, Dupixent Shines, EPS View Up

by Zacks Equity Research

Sanofi (SNY) beats estimates for second-quarter earnings. Key immunology drug Dupixent drives sales. The company ups its earnings growth expectations for the year.

What's in Store for Array BioPharma (ARRY) in Q4 Earnings?

by Zacks Equity Research

Array BioPharma's (ARRY) Braftovi-Mektovi combination therapy is likely to drive fourth-quarter sales.

Should You Buy Eli Lilly (LLY) Ahead of Earnings?

by Zacks Equity Research

Eli Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Kinjel Shah headshot

Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment

by Kinjel Shah

AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.

Mitchell Moore headshot

Eli Lilly (LLY) Stock Down 6.8% in 2019: Can Q2 Earnings Boost Performance?

by Mitchell Moore

Eli Lilly and Company (LLY) stock is down 6.8% YTD, slightly worse than a large-cap pharma average of -5.4%. Let's dive into Eli Lilly and see what to expect from its results heading into its Q2 earnings report that will be released before the market opens on Tuesday, July 30.